Common Contracts
7 similar Underwriting Agreement contracts by Daseke, Inc., Achillion Pharmaceuticals Inc, Avalon Pharmaceuticals Inc, others
7,500,000 Shares DASEKE, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2018 • Daseke, Inc. • Transportation services • New York
Daseke, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), and a certain shareholder of the Company named in Schedule II hereto (the “Selling Shareholder”) proposes to sell to the several Underwriters, an aggregate of 7,500,000 shares (the “Firm Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”), of which 7,420,000 shares are to be issued and sold by the Company and 80,000 shares are to be sold by the Selling Shareholder as set forth in Schedule II hereto. The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,125,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred
Unitil Corporation 600,000 Shares Common Stock (No Par Value) Underwriting AgreementUnderwriting Agreement • December 13th, 2017 • Unitil Corp • Electric & other services combined • New York
The following letter is be provided by special counsel to the Company, subject to customary assumptions, limitations and qualifications. All capitalized terms used herein without definition shall have the meanings ascribed thereto in the Underwriting Agreement.
5,292,000 Shares DASEKE, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 22nd, 2017 • Daseke, Inc. • Transportation services • New York
Daseke, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), and certain shareholders of the Company named in Schedule II hereto (the “Selling Shareholders”) severally propose to sell to the several Underwriters, an aggregate of 5,292,000 shares (the “Firm Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”), of which 4,882,167 shares are to be issued and sold by the Company and 409,833 shares are to be sold by the Selling Shareholders in the respective amounts set forth opposite their respective names in Schedule II hereto. The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 793,800 shares of Common Stock (the “Option Shares”)
UNDERWRITING AGREEMENT FOR EQUITY OFFERING 3,660,000 Shares Fluidigm Corporation Common Stock ($0.001 Par Value) August 16, 2012Underwriting Agreement • August 16th, 2012 • Fluidigm Corp • Laboratory analytical instruments • New York
Fluidigm Corporation, a Delaware corporation (the “Company”) proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of 3,660,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 549,000 shares of Common Stock (the “Option Shares”) as set forth below.
ACHILLION PHARMACEUTICALS, INC. 10,275,000 Shares of Common Stock UNDERWRITING AGREEMENT January 22, 2010Underwriting Agreement • January 22nd, 2010 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • New York
Achillion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Roth Capital Partners, LLC (“Roth”), Noble Financial Capital Markets and National Securities Corporation (each, an “Underwriter” and, collectively, the “Underwriters”) an aggregate of 10,275,000 shares (the “Securities”) of its common stock, par value $0.001 per share (the “Common Stock”).
4,200,000 Shares FTI Consulting, Inc. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • October 3rd, 2007 • Fti Consulting Inc • Services-management consulting services • New York
FTI Consulting, Inc., a Maryland corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of 4,200,000 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 630,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
2,750,000] Shares AVALON PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 9th, 2005 • Avalon Pharmaceuticals Inc • Pharmaceutical preparations • Maryland
